1
|
Gallone G, Armeni P, Verheye S, Agostoni P, Timmers L, Campo G, Ielasi A, Sgura F, Tarantini G, Rosseel L, Zivelonghi C, Leenders G, Stella P, Tebaldi M, Tespili M, D'Amico G, Baldetti L, Ponticelli F, Colombo A, Giannini F. Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients. EUROPEAN HEART JOURNAL. QUALITY OF CARE & CLINICAL OUTCOMES 2021; 6:32-40. [PMID: 31124556 DOI: 10.1093/ehjqcco/qcz027] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/20/2019] [Revised: 05/01/2019] [Accepted: 05/17/2019] [Indexed: 11/13/2022]
Abstract
AIMS The coronary sinus Reducer is a percutaneous device proven to improve angina symptoms in refractory angina (RA). We evaluated its potential cost-effectiveness and impact on the healthcare resource use. METHODS AND RESULTS Angina-related healthcare resource usage and quality-of-life data were collected for 215 consecutive RA patients undergoing Reducer implantation in Belgium, the Netherlands, and Italy. Costs were assessed from each country's healthcare system perspective. Data from the date of RA diagnosis to Reducer implantation [Standard-of-Care (SoC)-period] and from Reducer implantation to follow-up (Reducer-period) were compared: during Reducer-period, a significant reduction in angina-driven hospitalizations, outpatient visits, coronary angiograms, and percutaneous coronary interventions per patient-year was observed, translating into significantly reduced costs per patient-year. To assess cost-effectiveness, costs and utilities of 1-year SoC were compared with those of 1-year Reducer-period. Assumptions on Reducer efficacy duration were further explored with modelled projections. Reducer was associated with higher quality-adjusted life years (QALYs: 0.665 vs. 0.580, P < 0.001) and incremental costs, yielding incremental cost-effectiveness ratios (ICERs) of 53 197, 34 948, 63 146 €/QALY gained in Belgium, the Netherlands, and Italy, respectively. Under both the assumptions of 2 and 3 years Reducer effect duration with a 30%-year efficacy decrease, the device yielded ICERs in the range of 1977-20 796 €/QALY gained. CONCLUSION In patients with RA, Reducer device decreases healthcare resource use and related costs. In a limited 1-year timeframe, Reducer is consistently cost-effective according to a range of cost-effectiveness thresholds. Under the explored assumptions, the device yields cost-effectiveness ratios suggesting high value from all the considered perspectives.
Collapse
Affiliation(s)
- Guglielmo Gallone
- Unit of Cardiovascular Interventions, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Patrizio Armeni
- SDA Bocconi School of Management and CERGAS (Centre for Research on Social and Healthcare Management), Bocconi University, Milan, Italy
| | - Stefan Verheye
- Cardiovascular Center, Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium
| | | | - Leo Timmers
- Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Gianluca Campo
- Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy.,Maria Cecilia Hospital, GVM Care & Research, E.S: Health Science Foundation, Cotignola, Italy
| | - Alfonso Ielasi
- Division of Cardiology, ASST Bergamo Est, "Bolognini" Hospital, Seriate, Italy
| | - Fabio Sgura
- Interventional Cardiology Unit, Sant'Ambrogio Cardio-Thoracic Center, Milan, Italy
| | - Giuseppe Tarantini
- Institute of Cardiology, Policlinico Hospital, University of Modena and Reggio Emilia, Modena, Italy.,Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
| | - Liesbeth Rosseel
- Cardiovascular Center, Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium
| | - Carlo Zivelonghi
- Department of Cardiology, Sint Antonius Ziekenhuis, Nieuwegein, The Netherlands
| | - Geert Leenders
- Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Pieter Stella
- Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Matteo Tebaldi
- Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy.,Maria Cecilia Hospital, GVM Care & Research, E.S: Health Science Foundation, Cotignola, Italy
| | - Maurizio Tespili
- Division of Cardiology, ASST Bergamo Est, "Bolognini" Hospital, Seriate, Italy
| | - Gianpiero D'Amico
- Institute of Cardiology, Policlinico Hospital, University of Modena and Reggio Emilia, Modena, Italy.,Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
| | - Luca Baldetti
- Unit of Cardiovascular Interventions, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Francesco Ponticelli
- Unit of Cardiovascular Interventions, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Antonio Colombo
- Maria Cecilia Hospital, GVM Care & Research, E.S: Health Science Foundation, Cotignola, Italy
| | - Francesco Giannini
- Maria Cecilia Hospital, GVM Care & Research, E.S: Health Science Foundation, Cotignola, Italy
| |
Collapse
|
2
|
Henry TD, Williams B, Satran D. Rebuttal: Response to severe coronary disease not amenable to revascularization—Are the series clearly defined? Catheter Cardiovasc Interv 2014; 84:E2-3. [DOI: 10.1002/ccd.22733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2010] [Accepted: 07/13/2010] [Indexed: 11/08/2022]
Affiliation(s)
| | | | - Daniel Satran
- Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
| |
Collapse
|